[go: up one dir, main page]

MX2023006881A - Antagonistas del receptor de adenosina a2a. - Google Patents

Antagonistas del receptor de adenosina a2a.

Info

Publication number
MX2023006881A
MX2023006881A MX2023006881A MX2023006881A MX2023006881A MX 2023006881 A MX2023006881 A MX 2023006881A MX 2023006881 A MX2023006881 A MX 2023006881A MX 2023006881 A MX2023006881 A MX 2023006881A MX 2023006881 A MX2023006881 A MX 2023006881A
Authority
MX
Mexico
Prior art keywords
sub
adenosine
receptor
antagonists
compounds
Prior art date
Application number
MX2023006881A
Other languages
English (en)
Inventor
Clive Mccarthy
Benjamin Moulton
Original Assignee
Adorx Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adorx Therapeutics Ltd filed Critical Adorx Therapeutics Ltd
Publication of MX2023006881A publication Critical patent/MX2023006881A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a los compuestos de la fórmula (I) que se muestran a continuación: (ver fórmula) en donde R0, R1, R2, R3 y A son cada uno como se define en la solicitud. La presente invención también se refiere a procesos para la preparación de estos compuestos, a composiciones farmacéuticas que los comprenden, y a su uso en el tratamiento contra enfermedades o afecciones en las que está implicada la actividad del receptor de adenosina A2a, tal como, por ejemplo, cáncer.
MX2023006881A 2020-12-11 2021-12-10 Antagonistas del receptor de adenosina a2a. MX2023006881A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2019622.6A GB202019622D0 (en) 2020-12-11 2020-12-11 Antagonist compounds
PCT/GB2021/053252 WO2022123272A1 (en) 2020-12-11 2021-12-10 Antagonists of the adenosine a2a receptor

Publications (1)

Publication Number Publication Date
MX2023006881A true MX2023006881A (es) 2023-07-26

Family

ID=74188755

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023006881A MX2023006881A (es) 2020-12-11 2021-12-10 Antagonistas del receptor de adenosina a2a.

Country Status (11)

Country Link
US (1) US20240083904A1 (es)
EP (1) EP4259629A1 (es)
JP (1) JP2023552650A (es)
KR (1) KR20230118162A (es)
CN (1) CN116888119A (es)
AU (1) AU2021397402A1 (es)
CA (1) CA3201252A1 (es)
GB (1) GB202019622D0 (es)
IL (1) IL303492A (es)
MX (1) MX2023006881A (es)
WO (1) WO2022123272A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250004779A (ko) 2022-04-13 2025-01-08 길리애드 사이언시즈, 인코포레이티드 Trop-2 발현 암을 치료하기 위한 병용 요법
CA3260113A1 (en) * 2022-06-29 2025-06-07 Hangzhou Synrx Therapeutics Biomedical Technology Co., Ltd. FIVE-LINKED AND SIX-LINKED NITROGEN COMPOUND, AND INTERMEDIATE, PROCESS OF PREPARATION AND ASSOCIATED USE
WO2024259945A1 (zh) * 2023-06-19 2024-12-26 杭州圣域生物医药科技有限公司 五元并六元含氮化合物、其制备方法和应用
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA200645A (en) 1920-06-01 E. Batie Joseph Machine for engaging ferrules with wheel spokes
DE3542661A1 (de) * 1985-12-03 1987-06-04 Bayer Ag Imidazopyridazinalkensaeureamide, verfahren zu ihrer herstellung, zwischenprodukte zu ihrer herstellung
JP4758909B2 (ja) * 2003-12-31 2011-08-31 シェーリング−プラウ・リミテッド イミダゾ［１，２−ｂ］ピリダジン誘導体を使用することによる動物における寄生生物の制御
EP1832588A4 (en) * 2004-12-28 2009-09-02 Takeda Pharmaceutical CONDENSED IMIDAZOLE COMPOUND AND ITS USE
JP2009502734A (ja) * 2005-07-29 2009-01-29 アステラス製薬株式会社 Ｌｃｋ阻害剤としての縮合複素環
FR2918061B1 (fr) * 2007-06-28 2010-10-22 Sanofi Aventis Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique.
WO2009027733A1 (en) * 2007-08-24 2009-03-05 Astrazeneca Ab (2-pyridin-3-ylimidazo[1,2-b]pyridazin-6-yl) urea derivatives as antibacterial agents
US7868001B2 (en) * 2007-11-02 2011-01-11 Hutchison Medipharma Enterprises Limited Cytokine inhibitors
EP2103614A1 (en) * 2008-03-18 2009-09-23 Santhera Pharmaceuticals (Schweiz) AG Substituted imidazopyrimidine, imidazopyrazine and imidazopyridazine derivatives as melanocortin-4 receptor modulators
EP2210891A1 (en) * 2009-01-26 2010-07-28 Domain Therapeutics New adenosine receptor ligands and uses thereof
WO2011137587A1 (en) * 2010-05-06 2011-11-10 Hutchison Medipharma Limited Cytokine inhibitors
TWI617559B (zh) * 2010-12-22 2018-03-11 江蘇恆瑞醫藥股份有限公司 ２－芳基咪唑并［１，２－ｂ］嗒．２－苯基咪唑并［１，２－ａ］吡啶，和２－苯基咪唑并［１，２－ａ］吡衍生物
LT3370768T (lt) 2015-11-03 2022-05-25 Janssen Biotech, Inc. Antikūnai, specifiškai surišantys pd-1, ir jų panaudojimas
US10973820B2 (en) * 2017-12-13 2021-04-13 Facio Intellectual Property B.V. Compounds for treatment of diseases related to DUX4 expression
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies

Also Published As

Publication number Publication date
CA3201252A1 (en) 2022-06-16
KR20230118162A (ko) 2023-08-10
WO2022123272A1 (en) 2022-06-16
JP2023552650A (ja) 2023-12-18
AU2021397402A9 (en) 2024-02-08
IL303492A (en) 2023-08-01
GB202019622D0 (en) 2021-01-27
US20240083904A1 (en) 2024-03-14
CN116888119A (zh) 2023-10-13
AU2021397402A1 (en) 2023-07-13
EP4259629A1 (en) 2023-10-18

Similar Documents

Publication Publication Date Title
MX2022013946A (es) Antagonistas del receptor de adenosina a2a.
MX2023006881A (es) Antagonistas del receptor de adenosina a2a.
EP4620533A3 (en) Antagonist compounds
MX2022013223A (es) [1,3]diazino[5,4-d]pirimidinas como inhibidores de her2.
MX2023005636A (es) Inhibidores de bcl6 derivados de bencimidazolona.
ZA202107444B (en) Nlrp3 inflammasome inhibitors
MX2021013110A (es) Compuestos heterociclicos como inhibidores de la cinasa ret.
MA38380A1 (fr) Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr)
UA86614C2 (ru) Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата
MX2022007842A (es) Derivados biciclicos sustituidos de piperidina utiles como activadores de celulas t.
JOP20220131A1 (ar) مركبات أمينو كينولون تحمل بدائل تستخدم كمثبطات لـ dgkalpha من أجل تنشيط المناعة
EP4104837A3 (en) Heterocyclic compounds as ret kinase inhibitors
GEAP202515818A (en) Amino quinazoline derivatives as p2x3 inhibitors
MX2020010805A (es) Inhibidores de bcl6.
EP4371562A3 (en) 2-quinolone derived inhibitors of bcl6
MX2009008953A (es) Compuestos como inhibidores de angiogenesis.
MX2009009843A (es) Compuestos espiro sustituidos como inhibidores de la angiogenesis.
PH12021552036A1 (en) Substituted pyrrolopyridines as jak inhibitors
BR112022001628A2 (pt) [1,2,4]triazolo[1,5-c]quinazolin-5-aminas
EA201992090A1 (ru) ДЕЙТЕРИРОВАННЫЕ СОЕДИНЕНИЯ ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА
MX2021008510A (es) Derivados de tiazolopiridina como antagonistas del receptor de adenosina.
MX2024012937A (es) Inhibidores del receptor del factor de crecimiento epidérmico en el tratamiento de cáncer
MX2023012039A (es) Compuestos bicíclicos fusionados sustituidos como inhibidores de parp y uso de estos.
MX2023003516A (es) Inhibidores no covalentes de la cinasa dependiente de ciclina 7 (cdk7).
PH12022552553A1 (en) Substituted 3-phenoxyazetidin-1-yl-pyrazines having gpr52 agonistic activity